Women, Children s and Sexual Health Division Maternity Services. MMR / Rubella Vaccine for Postnatal Woman
|
|
- Barbra Clarke
- 7 years ago
- Views:
Transcription
1 Women, Children s and Sexual Health Division Maternity Services Guideline: MMR - Rubella Vaccination for Postnatal Woman 1. Introduction Rubella vaccine is usually given in childhood along with the measles and mumps vaccines as a part of the MMR vaccine. Before the introduction of this vaccine there were around 43 cases each year of Congenital Rubella Syndrome. Recently this has reduced to an average of less than two cases per year. The purpose of the guideline is to offer rubella vaccination to all postnatal women known to be non-immune at this hospital, to reduce the risk of congenital abnormalities in the future. This guideline is intended to be for the use of midwives and obstetricians and applies to both the home and hospital setting, regardless of type of birth. 2. Aims and objectives All women will be offered screening for rubella immunity during pregnancy. On no account should any pregnant woman be vaccinated Women who are found to be not immune to rubella should be advised to avoid contact with anyone thought to be infectious. Following delivery, women who are not rubella immune must be offered rubella vaccination. This should be prescribed and administered prior to discharge. 3. Definitions Rubella is an infectious viral disease associated with a rash, which in adults can also cause joint pain and arthritis. It has an incubation period of days. Individuals suffering from rubella are infectious from one week before the onset of rash until four days afterwards. Most women of childbearing age are immune to rubella because either they have been vaccinated prior to pregnancy or they had the illness during childhood. However, in recent years a fall in the uptake of MMR (mumps, measles and rubella) vaccination in children has raised concerns about a possible increase in cases Although rubella is a mild disease, it can have devastating effects on the fetus if a woman contracts it early in her pregnancy. The risk is of congenital rubella syndrome, a condition resulting in profound birth defects such as; Cataracts and other eye defects Deafness Cardiac abnormalities Microcephaly Retardation of intra-uterine growth Inflammatory lesions of brain, liver, lungs and bone marrow. (DH 2006) Page 1 of 10
2 4. Incidence The greatest risk is from infection in the first 8-10 weeks of pregnancy, with 90% of cases resulting in severe birth defects. At weeks fetal damage occurs in 50% of cases and at 17 weeks this reduces considerably. After this stage, birth defects rarely result from maternal rubella infection (MacLean, RCOG 2001, DH 2006) 5. Rubella Vaccine, MMR is a vaccine consisting of a mixture of live attenuated measles, mumps and rubella virus. A single dose of this vaccine confers around % protection to rubella virus but a lower level of protection against measles and mumps and thus the current recommendation is for two separate doses of MMR to be given to those found to be nonimmune. 6. Recommendations for Practice/Administration (see Appendix Three for practice points) Post-natal prophylaxis with MMR vaccine is recommended for all postnatal women known to be non-immune to rubella Non-immunity is reported as IgG not detected Appendix One In most cases non-immunity is identified in the antenatal period. In this case the women should be informed of the result and provided with appropriate information and offered postnatal MMR vaccination, thus ensuring immunity in future pregnancies The MMR vaccine must be prescribed on a medication chart by an obstetrician and written consent gained prior to administration, Appendix Two A stock of six MMR vaccines will be kept in the fridge on the postnatal ward and two delivery suite ready for administration when required. The dose to be administered to confer adequate immunity to all three elements of MMR is two doses of 0.5ml of MMR vaccine, at least one month apart. The vaccine should be given immediately prior to discharge as an intramuscular or subcutaneous injection. The vaccine should be administered into the deltoid muscle in the upper arm (as best practice) or anterior-lateral thigh. Individuals with a bleeding disorder should be given the injection by deep subcutaneous injection to reduce the risk of bleeding. It must be clearly documented in the woman s handheld records that the immunisation process has been commenced in the postnatal care plan and discharge details. Lactating women of normal full term infants can receive MMR vaccination during lactation Women requiring the MMR vaccination, who plan to transfer from the Lexden ward to either Harwich or Clacton midwife led units should be vaccinated prior to transfer. Page 2 of 10
3 The MMR vaccine should not be given to pregnant women The information leaflet accompanying the vaccine (from the supplier) should be consulted prior to giving the vaccination. This will ensure correct administration of the vaccine and that contraindications are known to the person who is administering the vaccine. Staff are also able to refer to BNF (British National Formulary) available in clinical areas. However, in general: The vaccine should not be given to anyone with a acute severe febrile condition The vaccine must not be given to anyone allergic to neomycin The MMR vaccine is not recommended for women with severe immunosuppression. The MMR vaccine can be given to HIV positive women with or without moderate immuno-suppression. (DH Green Book 2006) If a woman has received blood products such as whole blood, packed red cells and intravenous immunoglobulin, vaccination should be deferred for 3 months, this information should be given to the woman and documented on the discharge summary to inform her General Practitioner. (DH Green Book 2006) Women who have experienced anaphylaxis after egg ingestion should be vaccinated with extreme caution, with adequate treatment for anaphylaxis on hand should such a reaction occur 6.1 Adverse Reactions Severe allergic reactions are rare (<1, 10,000) but may consist of sudden wheeziness, chest pain or tightness, swelling of the eyelids, face, lips, mouth or tongue or generalised urticaria. Mild reactions such as fever, sore throat, rash and joint pain can occur following vaccination. Symptoms usually begin one to three weeks after immunisation and are transient. For anaphylaxis algorithm see appendix Four 7. Consent and Documentation Written consent must be obtained and documented in the woman s handheld healthcare records prior to administration. Appendix Two All parts of the consent form should be completed: copies are available on Lexden ward, the completed form should then be photocopied 3 times. The original form should then be retained in the women s health records; One copy sent to the GP along with the other discharge summary letter. One copy issued to the woman with a full explanation and then placed in the discharge envelope Page 3 of 10
4 When the MMR vaccine is given, this must be clearly recorded in the woman s handheld healthcare records and the prescription chart should be signed with the batch number of the MMR vaccine, with the correct date, time, dosage and route of administration The Administration of vaccine should also be communicated clearly in both the postnatal care plan and discharge details (where a copy of the consent form should be placed) along with the need for the second dose of MMR vaccine to be administered via GP s surgery. Equally, if a woman declines the vaccination this should also be recorded clearly in her handheld healthcare records and on the discharge summary. 8. Advice to women following Vaccination The patient information leaflet (PIL) from the MMR vaccine should be given to the woman. A woman who is breastfeeding can be safely vaccinated Pregnancy should be avoided for at least one month following vaccination, with the use of adequate contraception. The vaccine is not transmitted from vaccinated individuals to susceptible contacts. Therefore there is no risk to pregnant women contact with recently immunised individuals. There is no known risk or adverse effect, associated with receiving of the MMR vaccine in women already immune to measles and mumps as these women will already have antibodies to these two viruses A second dose of MMR vaccine is recommended at least one month following the first, this would usually be administered via the GP. Immunity to rubella should be confirmed by a blood test eight weeks following the second vaccination via the GP. 9. Staffing and Training Registered Nurses and Midwives must be currently registered with the Nursing and Midwifery Council (NMC); they will practise according to the standard laid down by the NMC. A copy of this guideline will be available in hard copy in all areas and on the Trust intranet site. The Practice Development Midwife at Colchester General Hospital will be available for training sessions for all midwives requiring updates in performing deltoid injections. 10. Infection Prevention All staff should follow Trust guidelines on infection control by ensuring that they effectively decontaminate their hands before and after each procedure. Page 4 of 10
5 All staff should ensure that they follow Trust guidelines on infection control when carrying out procedures 11. Monitoring compliance The risk management team will review all Datix and complaints. Any immediate training or educational issues relating to lack of compliance with this guideline will be addressed on a one to one basis. All incidents and trends analysis will be reviewed at the Maternity Risk Management Group meeting. 12. References British National Formulary Measles, Mumps and Rubella vaccine (MMR). Centre for Disease Control and Prevention (CDC) (2005) A detailed review of the epidemiology, pathogenesis, clinical features and management of rubella. Department of Health (1998) Immunisation against infectious diseases. Chapter 22, pp140. HMSO Department of Health (2003) Screening for infectious diseases in pregnancy; standards to support the UK antenatal screening programme. DoH August 2003 London Department of Health (2006) The Green Book. DoH Donalson L, Mullally S, Smith J and House R (2003) Protecting women against rubella: the switch from rubella vaccine to MMR. Joint chief medical, nursing and pharmaceutical officers circular, September 2003 DoH. MacLean AB, et al (2001) Infection and Pregnancy, RCOG Press London. National Institute of Clinical Excellence (2006) Routine postnatal care of women and their babies. NICE Clinical guideline 37. NICE, London/ WHO (2003) Vaccines, immunizations and biologicals. April Page 5 of 10
6 Dymphna Sexton-Bradshaw Associate Director of Women & Children's/ Head of Midwifery Women & Children s Division... Professor Khaled Consultant Obstetrician Screening Lead Anne Regan Lead Pharmacist Version Author Date Circulation Comments One Jenny Collins Matron for Postnatal & Community Supervisor of Midwives With Acknowledgements to the contribution from Derwent Valley & Mid-Essex maternity units. Tracy Baxter Antenatal and Newborn Screening Midwife 2012 Supervisors of midwives Thinking of getting pregnant Rubella Lea Page 6 of 10
7 Appendix One Results from Pathology as shown on screen / printed Rubella IgG: Detected Explanation; (Results Interpretation for Rubella Antibodies) (If result equals Detected patient is immune,) (unless there has been a recent contact with rubella). (If result equals NOT detected patient is not immune and rubella) (vaccination post partum is recommended.) Page 7 of 10
8 Appendix Two Consent for Postnatal MMR Vaccination Woman s Details Surname: First Name: Hospital No: NHS Number: D.O.B.: Address: Consultant: G.P. Name and address and courier no; 1. Have the reasons for MMR vaccination been explained? Yes 2. Is the woman aware of any side effects? Yes 3. Has the woman been informed of the need to avoid pregnancy for 1 month following vaccination? Yes 4. Is the woman aware that she should have a second dose of MMR from her GP at least one month after this initial dose and a blood test to confirm immunity, approximately eight weeks following the second vaccination? Yes 5. Has a copy of the Patient information leaflet been given to the woman? Yes 6. Has a copy of this form been attached to the GP discharge letter Yes Woman s Signature Batch number Dose given Given by Checked by Route Date Time Page 8 of 10
9 Please photocopy this completed form: retain the original in the woman s healthcare records, one copy attached to the GP discharge letter and second copy in the woman s discharge envelope. MMR VACCINE PRACTICE POINTS Appendix Three The MMR vaccine must be prescribed on a medication chart by an obstetrician & written consent gained prior to administration Appendix Two The vaccine should not be given to anyone with an acute febrile condition. The vaccine must not be given to anyone allergic to neomycin The MMR vaccine is not recommended for women with severe immunosuppression The MMR vaccine can be given to HIV positive with or without moderate immuno-suppression If a women has received blood products (such as whole blood, packed red cells & intravenous immunoglobulin), vaccination should be deferred for 3 months; this information should be given to the women & documented on the discharge summary to inform her GP Women who have had Anti-D this vaccine can be given but should be in the opposite arm The vaccine is not transmitted from vaccinated individuals to susceptible contacts. Therefore there is no risk to pregnant women contact with recently immunised individuals. For women transferring to the coastal Midwife-led units, for postnatal care, the vaccine can be administered prior to them leaving Colchester For women delivering in the Midwife led units, Vaccine should be administered prior to discharge. Women who have experienced anaphylaxis after egg ingestion should be vaccinated with extreme caution, with adequate treatment for anaphylaxis on hand should such a reaction occur Page 9 of 10
10 Anaphylaxis algorithm Appendix Four Anaphylactic Algorithum Page 10 of 10
Women, Children and Sexual Health Division Maternity Services. Guideline: Anti D- Prophylaxis
Women, Children and Sexual Health Division Maternity Services Guideline: Anti D- Prophylaxis 1. Introduction The National Institute for Clinical Excellence recommend routine antenatal anti-d prophylaxis
More informationBE SURE. BE SAFE. VACCINATE.
DON T GET OR GIVE THE FLU THIS YEAR THANK YOU Vaccination is the only protection. www.immunisation.ie BE SURE. BE SAFE. VACCINATE. FLU VACCINE 2013-2014 Healthcare workers prevent the spread of flu and
More informationVaccination against pertussis (whooping cough) - the replacement of Repevax with Boostrix -IPV an update for registered healthcare practitioners
Vaccination against pertussis (whooping cough) - the replacement of Repevax with Boostrix -IPV an update for registered healthcare practitioners Questions and Answers May 2014 Health Protection Scotland
More informationI B2.4. Design of the patient information leaflet for VariQuin
(English translation of official Dutch version) I B2.4. Design of the patient information leaflet for VariQuin Information for the Patient: Read this package leaflet carefully when you have some time to
More informationFacts About Chickenpox and Shingles for Adults
Facts About Chickenpox and Shingles for Adults What is chickenpox? Chickenpox, also known as varicella, is a very contagious disease caused by the varicella-zoster virus. It is spread easily through the
More informationFactsheet September 2012. Pertussis immunisation for pregnant women. Introduction
Factsheet September 2012 Pertussis immunisation for pregnant women Introduction The routine childhood immunisation programme has been very effective in reducing the overall numbers of cases of pertussis.
More informationNHS FORTH VALLEY Guidelines for Hepatitis B Vaccination in High Risk Groups
NHS FORTH VALLEY Guidelines for Hepatitis B Vaccination in High Risk Groups Approved 01/04/2012 Version 1.0 Date of First Issue 01/04/2012 Review Date 01/02/2014 Date of Issue 01/04/2012 EQIA Yes Author
More informationPertussis (whooping cough) immunisation for pregnant women the safest way to protect yourself and your baby
Factsheet September 2012 Pertussis (whooping cough) immunisation for pregnant women the safest way to protect yourself and your baby The routine childhood immunisation programme has been very effective
More informationVaccinations and Spina Bifida and Hydrocephalus
shinecharity.org.uk info@shinecharity.org.uk 42 Park Road Peterborough PE1 2UQ 01733 555988 Vaccinations and Spina Bifida and Hydrocephalus Vaccines are made from parts of bacteria or viruses that cause
More informationMother s blood test to check her unborn baby s blood group
Mother s blood test to check her unborn baby s blood group This leaflet explains why it is important to have a blood test to check the baby s blood group, so that only those who need it, receive anti-d
More informationRhD Negative and care in pregnancy
RhD Negative and care in pregnancy Exceptional healthcare, personally delivered RhD Negative and care in pregnancy What does RhD Negative mean? n The rhesus factor is found on the red blood cells. People
More informationThinking of getting pregnant?
Thinking of getting pregnant? Make sure you re protected against German measles the safest way to protect the health of you and your baby Catching German measles (rubella) can be very serious for your
More informationWhooping Cough Vaccine for Pregnant Women
Whooping Cough Vaccine for Pregnant Women What is whooping cough (pertussis)? Whooping cough (also known as pertussis) is a highly contagious illness that can be life threatening. The disease is most serious
More informationPertussis (whooping cough) immunisation for pregnant women
Factsheet September 2012 Pertussis (whooping cough) immunisation for pregnant women Immunisation DEPARTMENT OF HEALTH Rheynn Slaynt The routine childhood immunisation programme has been very effective
More informationFAQs on Influenza A (H1N1-2009) Vaccine
FAQs on Influenza A (H1N1-2009) Vaccine 1) What is Influenza A (H1N1-2009) (swine flu) 1? Influenza A (H1N1-2009), previously known as "swine flu", is a new strain of influenza virus that spreads from
More informationChickenpox in pregnancy: what you need to know
Chickenpox in pregnancy: what you need to know First published December 2003 Revised edition published November 2008 What is chickenpox? Chickenpox is a very infectious illness caused by a virus called
More information2 months Diptheria; Tetanus; Whooping Cough; Hib & Polio 1st dose Pneumococcal Conjugate Vaccination
IMMUNISATIONS You may want to know if your child should have routine immunisations and whether there could be an increased risk of complications because of the heart condition. We have sought the opinions
More informationThe flu vaccination WINTER 2016/17. Who should have it and why. Flu mmunisation 2016/17
The flu vaccination WINTER 2016/17 Who should have it and why Flu mmunisation 2016/17 The flu vaccination 1 Winter 2016/17 Helping to protect everyone, every winter This leaflet explains how you can help
More informationHuman Normal Immunoglobulin Solution for Intravenous Infusion.
CONSUMER MEDICINE INFORMATION (CMI) OCTAGAM Human Normal Immunoglobulin Solution for Intravenous Infusion. OCTAGAM is available in single use bottles of 20 ml, 50 ml, 100 ml and 200 ml. OCTAGAM contains
More informationRh D Immunoglobulin (Anti-D)
Document Number PD2006_074 Rh D Immunoglobulin (Anti-D) Publication date 29-Aug-2006 Functional Sub group Clinical/ Patient Services - Maternity Clinical/ Patient Services - Medical Treatment Population
More informationRubella. Questions and answers
Rubella Questions and answers What is rubella? Rubella, or German measles, is a mild disease caused by a virus. Before the MMR (measles, mumps and rubella) vaccine was used, rubella used to be common in
More informationswine flu vaccination:
swine flu vaccination: what you need to know Flu. Protect yourself and others. Contents What is swine flu?............... 3 About the swine flu vaccine....... 4 What else do I need to know?...... 8 What
More informationMINISTRY OF HEALTH PANDEMIC INFLUENZA A / H1N1 2009 VACCINE FREQUENTLY ASKED QUESTIONS
Government of the Republic of Trinidad and Tobago MINISTRY OF HEALTH PANDEMIC INFLUENZA A / H1N1 2009 VACCINE FREQUENTLY ASKED QUESTIONS Influenza vaccines are one of the most effective ways to protect
More informationChildren & Young People s Directorate. School Nursing Procedure For Administration of Immunisations
Children & Young People s Directorate School Nursing Procedure For Administration of Immunisations Author Mrs Gladys Bleakley & Mrs Barbara Ervine Directorate responsible for Children & Young Peoples this
More informationZika Virus. Fred A. Lopez, MD, MACP Richard Vial Professor Department of Medicine Section of Infectious Diseases
Zika Virus Fred A. Lopez, MD, MACP Richard Vial Professor Department of Medicine Section of Infectious Diseases What is the incubation period for Zika virus infection? Unknown but likely to be several
More informationInfluenza Vaccine Protocol Agreement (O.C.G.A. Section 43-34-26.1)
Influenza Vaccine Protocol Agreement (O.C.G.A. Section 43-34-26.1) This Influenza Vaccine Protocol Agreement (the "Protocol") authorizes the Georgia licensed pharmacists (the "Pharmacists") or nurses (
More informationChildhood Diseases and potential risks during pregnancy: (All information available on the March of Dimes Web Site.) http://www.modimes.
Childhood Diseases and potential risks during pregnancy: (All information available on the March of Dimes Web Site.) http://www.modimes.org/ Fifth disease (erythema infectiosum) is a common, mild, childhood
More informationIMPORTANT: PLEASE READ
PART III: CONSUMER INFORMATION combined hepatitis A (inactivated) and hepatitis B (recombinant) vaccine This leaflet is part III of a three-part "Product Monograph" published when was approved for sale
More informationMEDICATION GUIDE STELARA
MEDICATION GUIDE STELARA (stel ar a) (ustekinumab) Injection What is the most important information I should know about STELARA? STELARA is a medicine that affects your immune system. STELARA can increase
More informationTdap and MenC booster vaccines. Information for parents of children in First Year of second level school
Tdap and MenC booster vaccines Information for parents of children in First Year of second level school Tdap and MenC booster vaccines Information for parents of children in First Year of second level
More informationSummary of the risk management plan (RMP) for Accofil (filgrastim)
EMA/475472/2014 Summary of the risk management plan (RMP) for Accofil (filgrastim) This is a summary of the risk management plan (RMP) for Accofil, which details the measures to be taken in order to ensure
More informationMUMPS PUBLIC FREQUENTLY ASKED QUESTIONS
New Jersey Department of Health Vaccine Preventable Disease Program MUMPS PUBLIC FREQUENTLY ASKED QUESTIONS Date: April 17, 2014 DESCRIPTION OF MUMPS What is mumps? Mumps is a disease that is caused by
More information160S01105, Page 1 of 7. Human Hepatitis B Immunoglobulin, solution for intramuscular injection.
160S01105, Page 1 of 7 New Zealand Data Sheet Hepatitis B Immunoglobulin-VF NAME OF THE MEDICINE Human Hepatitis B Immunoglobulin, solution for intramuscular injection. DESCRIPTION Hepatitis B Immunoglobulin-VF
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. [new-ka la]
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr NUCALA [new-ka la] mepolizumab lyophilized powder for subcutaneous injection Read this carefully before you start
More informationInformation for you Abortion care
Information for you Abortion care Published in February 2012 This information is for you if you are considering having an abortion. It tells you: how you can access abortion services the care you can expect
More informationHow long will it take to work? You may begin to feel better within a few days or it may take up to six weeks after your first treatment session.
Crohn's and Colitis UK Drug Treatment Information Improving life for people affected by inflammatory bowel diseases Infliximab This information leaflet aims to answer common questions you may have if you
More informationImporter / Manufacturer: MSD (THAILAND) LTD./ Merck & Co.,Inc., West Point, Pennsylvania 19486 SUMMARY OF PRODUCT CHARACTERISTICS
Registration No. 1C 68/47(NC) Importer / Manufacturer: MSD (THAILAND) LTD./ Merck & Co.,Inc., West Point, Pennsylvania 19486 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICAL PRODUCT VARIVAX [Varicella
More informationROYAL HOSPITAL FOR WOMEN
HEPATITIS B POSITIVE MOTHERS AND THEIR BABIES This LOP is developed to guide clinical practice at the Royal Hospital for Women. Individual patient circumstances may mean that practice diverges from this
More information2 P age. Babies from Birth to Age 2
Contents Babies from Birth to Age 2... 2 Vaccines give parents the power... 2 Vaccines are recommended throughout our lives... 3 Talk to your doctor... 3 Vaccines are very safe... 3 Whooping Cough (Pertussis)...
More informationInformation for you Treatment of venous thrombosis in pregnancy and after birth. What are the symptoms of a DVT during pregnancy?
Information for you Treatment of venous thrombosis in pregnancy and after birth Published in September 2011 What is venous thrombosis? Thrombosis is a blood clot in a blood vessel (a vein or an artery).
More informationTEMPORARY PROGRAMME PERTUSSIS VACCINATION FOR PREGNANT WOMEN
TEMPORARY PROGRAMME PERTUSSIS VACCINATION FOR PREGNANT WOMEN Richard Smithson Neil Irvine Maureen McCartney Consultant Health Protection October 2012 Pertussis/whooping cough The disease Whooping Cough
More informationVARICELLA ZOSTER (VZ) VIRUS, CHICKENPOX & SHINGLES GUIDANCE
VARICELLA ZOSTER (VZ) VIRUS, CHICKENPOX & SHINGLES GUIDANCE Summary This guidance provides background information on varicella zoster (VZ), chickenpox and shingles and sets out the infection control measures
More informationMedicines Management
Medicines Management Patient Group Direction for the Supply/administration of Adrenaline (Epinephrine) for Treatment of Anaphylaxis by accredited community Pharmacists. Rationale To enable a pharmacist,
More informationTeriflunomide (Aubagio) 14mg once daily tablet
Teriflunomide (Aubagio) 14mg once daily tablet Exceptional healthcare, personally delivered Your Consultant Neurologist has suggested that you may benefit from treatment with Teriflunomide. The decision
More informationStepping toward a different treatment option LEARN WHAT ACTHAR CAN DO FOR YOU
FOR MS RELAPSES Stepping toward a different treatment option LEARN WHAT ACTHAR CAN DO FOR YOU As a person with multiple sclerosis (MS), you know firsthand the profound impact MS relapses can have on your
More informationIntravenous Immunoglobulin in Neurological disorders
Intravenous Immunoglobulin in Neurological disorders Exceptional healthcare, personally delivered What is Intravenous Immunoglobulin (IVIg)? Intravenous immunoglobulin (IVIg) is a blood product that combines
More informationExceptional People. Exceptional Care. Antenatal Appointment Schedule for Normal Healthy Women with Singleton Pregnancies
Exceptional People. Exceptional Care. Antenatal Appointment Schedule for Normal Healthy Women with Singleton Pregnancies First Antenatal Contact with the GP Obtain medical and obstetric history. Measure
More informationIMPORTANT DRUG WARNING Regarding Mycophenolate-Containing Products
Dear Healthcare Provider: Mycophenolate REMS (Risk Evaluation and Mitigation Strategy) has been mandated by the FDA (Food and Drug Administration) due to postmarketing reports showing that exposure to
More informationDocument Title: PCT Doc Ref.: Version No.: 1/2014. Local Doc Ref.:
Document Title: Patient Group Direction (PGD) for the vaccination of pregnant women (gestation week 28 onwards) and new mothers against pertussis (Whooping Cough) using Boostrix-IPV (Diphtheria, tetanus,
More informationRegistered Nursing Health Requirements Checklist
Registered Nursing Health Requirements Checklist The applicant must: 1). Upload the original completed form to your CertifiedBackground profile. 2). Retain a copy for your records. www.certifiedbackground.com
More informationMENINGOCOCCAL GROUP B VACCINE (BEXSERO) Information for Health Professionals
MENINGOCOCCAL GROUP B VACCINE (BEXSERO) Information for Health Professionals What is Bexsero vaccine? Bexsero is a meningococcal Group B (MenB) vaccine which is indicated for the active immunisation of
More informationMEDICATION GUIDE mitoxantrone (mito-xan-trone) for injection concentrate
MEDICATION GUIDE mitoxantrone (mito-xan-trone) for injection concentrate Read this Medication Guide before you start receiving mitoxantrone and each time you receive mitoxantrone. There may be new information.
More informationH1N1 Flu Vaccine Available to All Virginia Beach City Public Schools Students
V i r g i n i a B e a c h C i t y P u b l i c S c h o o l s apple-a-day F o r O u r F a m i l y o f I n t e r e s t e d C i t i z e n s Special Edition H1N1 Flu Vaccine Available to All Virginia Beach
More informationWhooping cough and pregnancy
Whooping cough and pregnancy Your questions answered on how to help protect your baby 2014 edition the safest way to protect yourself and your baby 1 There is a lot of whooping cough around at the moment
More informationVaccination against pertussis (Whooping cough) for pregnant women- 2014. Information for healthcare professionals
Vaccination against pertussis (Whooping cough) for pregnant women- 2014 Information for healthcare professionals About Public Health England Public Health England s mission is to protect and improve the
More informationProtecting your baby against meningitis and septicaemia
Protecting your baby against meningitis and septicaemia caused by meningococcal B bacteria MenB vaccine now available! Information about the MenB vaccine and recommended paracetamol use mmunisation The
More informationIMMUNIZATION REQUIREMENTS FOR SCHOOL CHILDREN
10-144 DEPARTMENT OF HUMAN SERVICES BUREAU OF HEALTH Chapter 261: IMMUNIZATION REQUIREMENTS FOR SCHOOL CHILDREN A joint rule with 05-071 DEPARTMENT OF EDUCATION (COMMISSIONER) Chapter 126: IMMUNIZATION
More informationAPPENDIX I-A: INFORMED CONSENT BB IND 11184 Protocol CDC IRB #4167
APPENDIX I-A: INFORMED CONSENT BB IND 11184 Protocol CDC IRB #4167 INFORMED CONSENT FOR USE OF DIPHTHERIA ANTITOXIN (DAT) FOR SUSPECTED DIPHTHERIA CASES Investigational New Drug (IND) BB 11184 Protocol
More informationInformation on Measles and Whooping Cough: Vaccination and Disease
Information on Measles and Whooping Cough: Vaccination and Disease Vaccine s Mechanism of Action Vaccines expose the recipient to a small amount of an weakened organism. Through this exposure, the body
More informationVaccine Protocol Agreement. Name of Pharmacy: Address: City, State, Zip:
Vaccine Protocol Agreement Name of Pharmacy: Address: City, State, Zip: This Vaccine Protocol Agreement (the "Protocol") authorizes the Georgia licensed pharmacists (the "Pharmacists") or nurses ( Nurses
More informationA P P E N D I X SAMPLE FORMS
A P P E N D I X A SAMPLE FORMS Authorization for Disclosure Consent for HBV/HCV Antigens, HIV Antibody Documentation of Staff Education Employees Eligible for Hepatitis-B Vaccination Hepatitis-A Consent
More informationGuidelines for Vaccinating Pregnant Women
Guidelines for Vaccinating Pregnant Women U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Disease Control & Prevention Guidelines for Vaccinating Pregnant Women from Recommendations of the Advisory
More informationEastern Health MS Service. Tysabri Therapy. Information for People with MS and their Families
Eastern Health MS Service Tysabri Therapy Information for People with MS and their Families The Eastern Health MS Service has developed this information for you as a guide through what will happen to you
More informationUse the steps below to complete the CertifiedBackground (CB) electronic health record tracking process.
Medical Coding Health Requirements Checklist All MATC Health Science students are required to complete and upload health requirements prior to petitioning for courses which contain a clinical component.
More informationImmunization Healthcare Branch. Human Papillomavirus Vaccination Program Questions and Answers. Prepared by
Immunization Healthcare Branch Human Papillomavirus Vaccination Program Questions and Answers Prepared by Immunization Healthcare Branch (IHB), Defense Health Agency Last Updated: 02 Jan 14 www.vaccines.mil
More informationAnaphylaxis and other adverse events
Anaphylaxis and other adverse events Aim: To be able to manage anaphylaxis and other adverse events correctly Learning outcomes Define local and systemic adverse events Distinguish between anaphylaxis
More informationFLU VACCINATION - FREQUENTLY ASKED QUESTIONS
FLU VACCINATION - FREQUENTLY ASKED QUESTIONS SEASONAL FLU VACCINATION 2015 2016 As a health care worker, am I required to be vaccinated against influenza (the flu)? It is not mandatory to be vaccinated
More informationEmergency Treatment of an Anaphylactic Reaction in the Community Protocol
Emergency Treatment of an Anaphylactic Reaction in the Community Protocol Reference Number: NHSCT/09/216 Responsible Directorate: Children s Services Replaces (if appropriate): Northern Trust Departmental
More informationTdap booster vaccine for Health Care Workers Frequently Asked Questions for Health Professionals
Tdap booster vaccine for Health Care Workers Frequently Asked Questions for Health Professionals NEW items in 2013 Immunisation Guidelines for Ireland are in RED What is Tdap booster vaccine? Tdap is a
More informationHealth (Drugs and Poisons) Regulation 1996. Drug Therapy Protocol Midwives
Health (Drugs and Poisons) Regulation 1996 Drug Therapy Protocol Midwives Health Protection Unit Medicines Regulation and Quality PO Box 21 Fortitude Valley BC QLD 4006 Telephone (07) 3328 9808 Facsimile
More informationRituximab. Drug information Rituximab. This leaflet provides information on rituximab and will answer any questions you have about the treatment.
Drug information Rituximab Rituximab This leaflet provides information on rituximab and will answer any questions you have about the treatment. Arthritis Research UK produce and print our booklets entirely
More informationTdaP-Booster (tee-dee-ay-pee boo-ster)
New Zealand Consumer Medicine Information TdaP-Booster (tee-dee-ay-pee boo-ster) Tetanus, diphtheria and pertussis (acellular mono-component) vaccine (adsorbed, reduced antigen content) CONSUMER MEDICINE
More informationNurse Aide Training Program Application Checklist
Nurse Aide Training Program Application Checklist The following checklist must be completed before enrolling in the Nurse Aide Training course: Complete, sign, and date the Application Form Have the physical
More informationTitle. Nationality. Email
APPLICATION FORM Devonshire House, 582 Honeypot Lane, Stanmore, Middlesex, HA7 1JS PHONE NO: 020 8906 2001 FAX: 020 8905 6728 LICENSED BY CARE QUALITY COMMISSION Registered in England NO 3414273 PERSONAL
More informationLeflunomide Leflunomide
Drug information Leflunomide Leflunomide This leaflet provides information on leflunomide and will answer any questions you have about the treatment. Arthritis Research UK produce and print our booklets
More informationEar Infections Chickenpox chickenpox
Ear Chickenpox Infections chickenpox Chickenpox Chickenpox is a common, very contagious viral infection that over 90% of people get during childhood unless they have been immunised. After an infection,
More informationpatient group direction
DICLOFENAC v01 1/8 DICLOFENAC PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner
More informationChapter 3. Immunity and how vaccines work
Chapter 3 Immunity and how vaccines work 3.1 Objectives: To understand and describe the immune system and how vaccines produce immunity To understand the differences between Passive and Active immunity
More informationPolio and the Introduction of IPV
Polio and the Introduction of IPV Poliomyelitis (polio) is a highly infectious disease that is caused when a person is infected by the polio virus that invades the nervous system. Poliomyelitis can cause
More informationSTAFF SCREENING AND IMMUNISATION POLICY
2GETHER NHS FOUNDATION TRUST GLOUCESTERSHIRE HOSPITALS NHS FOUNDATION TRUST NHS GLOUCESTERSHIRE GLOUCESTERSHIRE CARE SERVICES STAFF SCREENING AND IMMUNISATION POLICY Version: 1 Consultation: Ratified by:
More informationMEDICATION GUIDE. PROCRIT (PRO KRIT) (epoetin alfa)
MEDICATION GUIDE PROCRIT (PROKRIT) (epoetin alfa) Read this Medication Guide: before you start PROCRIT. if you are told by your healthcare provider that there is new information about PROCRIT. if you are
More informationWhooping cough and pregnancy
Your guide to Vaccinations Whooping cough and pregnancy What you need to know and do to help protect your baby There is a lot of whooping cough around at the moment and babies who are too young to start
More informationProgram details inside. MyIgSource is open to all Primary Immunodeficiency (PI) patients and caregivers regardless of treatment.
Support for living hands-on Nancy Travel enthusiast living with PI Program details inside. MyIgSource is open to all Primary Immunodeficiency (PI) patients and caregivers regardless of treatment. Please
More informationZOVIRAX Cold Sore Cream
Data Sheet ZOVIRAX Cold Sore Cream Aciclovir 5% w/w Presentation Topical cream Indications ZOVIRAX Cold Sore Cream is indicated for the treatment of Herpes simplex virus infections of the lips and face
More informationThe timing of vaccination with respect to anaesthesia and surgery. 1. Surgery following immunisation with inactivated vaccines
The timing of vaccination with respect to anaesthesia and surgery Main recommendations: 1. Surgery following immunisation with inactivated vaccines Delay surgery 48 hours post vaccination to avoid postvaccination
More informationMIAMI DADE COLLEGE MEDICAL CAMPUS SCHOOL OF HEALTH SCIENCES EMERGENCY MEDICAL SERVICES Emergency Medical Technician (EMT) Application Packet
MEDICAL CAMPUS SCHOOL OF HEALTH SCIENCES EMERGENCY MEDICAL SERVICES Emergency Medical Technician (EMT) Application Packet Student Name (Print) Student Number The information in this 8 - page packet must
More informationUCSF Communicable Disease Surveillance and Vaccination Policy
Office of Origin: Occupational Health Program I. PURPOSE To provide a sustainable, healthy and safe working environment for UCSF research laboratory staff, and animal research care staff and to prevent
More informationExplanation of Immunization Requirements
Explanation of Immunization Requirements CONTENTS Hepatitis A... 2 Hepatitis B... 3 Influenza... 4 Measles (Rubella), Mumps, and Rubella (MMR)... 5 Pertussis (Tdap)... 6 Tuberculosis (TB) Test... 7 Varicella/Chicken
More informationPatient Information Leaflet
Patient Information Leaflet METHOTREXATE We hope this fact sheet will provide you with some information about Methotrexate and answer some of the questions you may have. Methotrexate is available in tablet
More informationTrust Guideline for the use of the Modified Early Obstetric Warning Score (MEOWS) in detecting the seriously ill and deteriorating woman.
A clinical guideline recommended for use In: By: For: Key words: Written by: Supported by: Maternity Services. Obstetricians, Midwives and Midwifery Care Assistants. All women receiving care from maternity
More informationImmunization Healthcare Branch. Meningococcal Vaccination Program Questions and Answers. Prepared by
Immunization Healthcare Branch Meningococcal Vaccination Program Questions and Answers Prepared by Immunization Healthcare Branch (IHB), Defense Health Agency Last Updated: 27 Mar 06 www.vaccines.mil 877-GET-VACC
More informationAddition of vaccination against hepatitis B infection and change of the HPV vaccination programme
Change to DENMARK S CHILDHOOD VACCINATION PROGRAMME 2014 Addition of vaccination against hepatitis B infection and change of the HPV vaccination programme 2014 Addition to the Danish Health and Medicines
More informationDrug Treatment Information for patients with Inflammatory Bowel Disease. Infliximab
Drug Treatment Information for patients with Inflammatory Bowel Disease Infliximab Improving life for people affected by Colitis and Crohn s Disease National Association For Colitis and Crohn s Disease
More informationLEFLUNOMIDE (Adults)
Shared Care Guideline DRUG: Introduction: LEFLUNOMIDE (Adults) Indication: Disease modifying drug for rheumatoid arthritis and psoriatic arthritis Licensing Information: Disease modifying drug for active
More informationInfluenza Vaccine Frequently Asked Questions. Influenza Control Program
Influenza Vaccine Frequently Asked Questions Influenza Control Program Influenza or the flu can be a serious contagious disease, which is spread by droplet transmission through close contact with an infected
More informationPre-school immunisations
Pre-school immunisations A guide to vaccinations at three years and four months of age the safest way to protect your child The complete routine childhood immunisation programme These booklets describe
More informationEnhanced Service Specification. Pertussis (pregnant women) vaccination programme 2015/16
Enhanced Service Specification Pertussis (pregnant women) vaccination programme 2015/16 NHS England INFORMATION READER BOX Directorate Medical Commissioning Operations Patients and Information Nursing
More informationAccent on Health Obgyn, PC HERPES Frequently Asked Questions
1. What is herpes? 2. How common is herpes? 3. Is there a cure for herpes? 4. What is oral herpes (cold sores)? 5. How is oral herpes spread? 6. What is genital herpes? 7. How is genital herpes spread?
More informationCore Topic 2. The immune system and how vaccines work
Core Topic 2 The immune system and how vaccines work Learning outcome To be able to describe in outline the immune system and how vaccines work in individuals and populations Learning objectives Explain
More informationLyme Disease in Pregnancy. Dr Sarah Chissell Consultant Obstetrician William Harvey Hospital, Kent
Lyme Disease in Pregnancy Dr Sarah Chissell Consultant Obstetrician William Harvey Hospital, Kent Conflict of interest My son has chronic Lyme disease Infections in pregnancy Transplacental infection Perinatal
More information